Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021.

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Pasadena. CA | Posted on April 16th, 2021

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3080187.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3080187.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the continuing impact of the COVID-19 pandemic, the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

The National Space Society Congratulates Blue Origin and Jeff Bezos for the Spectacular First Crewed Flight of the New Shepard: Well-Tested Suborbital Tourist Rocket Soars to 63 Miles; Opens New Frontiers July 21st, 2021

Unconventional superconductor acts the part of a promising quantum computing platform: If it looks like a duck, swims like a duck and quacks like a duck, then it probably is a duck. July 16th, 2021

Unlocking efficient light-energy conversion with stable coordination nanosheets: Scientists design a high-performance, self-powered, UV photodetector using 2D nanosheets that show record photocurrent stability under air exposure July 16th, 2021

The virus trap: Hollow nano-objects made of DNA could trap viruses and render them harmless July 16th, 2021

Nanomedicine

The virus trap: Hollow nano-objects made of DNA could trap viruses and render them harmless July 16th, 2021

NYUAD study maps nanobody structure, leading to new ways to potentially fight diseases July 4th, 2021

Optical tweezer technology tweaked to overcome dangers of heat June 25th, 2021

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress June 25th, 2021

Announcements

The National Space Society Congratulates Blue Origin and Jeff Bezos for the Spectacular First Crewed Flight of the New Shepard: Well-Tested Suborbital Tourist Rocket Soars to 63 Miles; Opens New Frontiers July 21st, 2021

Scientists create rechargeable swimming microrobots using oil and water July 16th, 2021

Scientists take first snapshots of ultrafast switching in a quantum electronic device: They discover a short-lived state that could lead to faster and more energy-efficient computing devices July 16th, 2021

Researchers discover a new inorganic material with lowest thermal conductivity ever reported July 16th, 2021

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Events/Classes

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress June 25th, 2021

NSS Announces Juno Project Scientist Dr. Scott Bolton as a Keynote Speaker at the 2021 Online ISDC: This Year’s Virtual Conference Streams Free to All June 24th, 2021

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress June 24th, 2021

NSS Fetes JPL’s Rob Manning and Robert Braun at the Online 2021 International Space Development Conference: This Year’s Virtual Conference Streams Free to All Beginning Thursday June 24th, 2021

Nanobiotechnology

The virus trap: Hollow nano-objects made of DNA could trap viruses and render them harmless July 16th, 2021

Scientists create rechargeable swimming microrobots using oil and water July 16th, 2021

NYUAD study maps nanobody structure, leading to new ways to potentially fight diseases July 4th, 2021

Putting functional proteins in their place: Using DNA-based assembly, scientists developed a method for creating designed and biologically active 2-D and 3-D protein arrays, which show promise for applications in structural biology, biomaterials, nanomedicine, and biocatalysis June 25th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project